NASDAQ: TPSTTempest Therapeutics Inc Stock
$7.28+0.03 (+0.41%)
Updated Apr 17, 2025
TPST Price
$7.28
Fair Value Price
$0.53
Market Cap
$331.12M
52 Week Low
$0.41
52 Week High
$7.72
P/E
-4.85x
P/B
17.31x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$41.84M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.17
Operating Cash Flow
-$33M
Beta
10.28
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TPST Overview
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TPST's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TPST
Ranked#453 of 463
Ranked#453 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important TPST news, forecast changes, insider trades & much more!
TPST News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TPST scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TPST ($7.28) is overvalued by 1,262.98% relative to our estimate of its Fair Value price of $0.53 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TPST ($7.28) is not significantly undervalued (1,262.98%) relative to our estimate of its Fair Value price of $0.53 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TPST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TPST due diligence checks available for Premium users.
Valuation
TPST fair value
Fair Value of TPST stock based on Discounted Cash Flow (DCF)
Price
$7.28
Fair Value
$0.53
Overvalued by
1,262.98%
TPST ($7.28) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TPST ($7.28) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TPST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TPST price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.85x
Industry
-177.72x
Market
27.98x
TPST price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
17.31x
Industry
4.05x
TPST is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TPST's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.8M
Profit Margin
0%
TPST's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$41.5M
Liabilities
$22.4M
Debt to equity
1.17
TPST's short-term assets ($31.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TPST's short-term assets ($31.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TPST's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TPST's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.1M
Investing
-$3.0k
Financing
$18.0M
TPST's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TPST vs Biotech Stocks
Tempest Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.